SOM Biotech performed a presentation at the University of Barcelona Summer Course dedicated to Rare Diseases. The course was held from the 5th to the 9th of July. Dr. Raúl Insa, CEO of the company, performed the presentation on the topic of drug repurposing for Rare Diseases.
The main objective of the course was to educate the students and the general public about the relevance of the different stages of drug development and the role of the patient organizations in finding solutions for these diseases.
Dr. Raúl Insa, CEO of SOM Biotech: It is important to maintain awareness of people about Rare Diseases and the challenges that the patients with those conditions face. Depending on the type of the disease, in many cases, the quality of life of the patients is significantly affected, and in other cases, they are always fatal with a very low expectancy of life. It is crucial for those patients to get the treatment before the deterioration of the disease, but considering that conventional drug development takes an average of 10.5 years, it is not always possible for those patients. As drug repositioning allows to leverage on the already known information about the drugs, patients can get the treatments at least free times earlier comparing with traditional drug development. Developing its pipeline focused on Rare Diseases, SOM Biotech has demonstrated that its approach of repurposing drugs for these conditions is not just a hypothesis since it is proved by the clinical evidence.